104 related articles for article (PubMed ID: 6204221)
1. [A new experimental approach to the specific immunotherapy for malignant brain tumor. Immunobiological characterization of T-cell growth factor].
Yamasaki T; Taguchi M; Namba Y; Hanaoka M; Miyatake S; Yamashita J; Handa H
Neurol Med Chir (Tokyo); 1983 Dec; 23(12):909-16. PubMed ID: 6204221
[No Abstract] [Full Text] [Related]
2. [A new experimental approach to the specific adoptive immunotherapy for malignant gliomas].
Yamasaki T
Nihon Geka Hokan; 1983 Nov; 52(6):783-801. PubMed ID: 6331809
[No Abstract] [Full Text] [Related]
3. An experimental approach to specific adoptive immunotherapy for malignant brain tumors.
Yamasaki T; Kikuchi H
Nihon Geka Hokan; 1989 Nov; 58(6):485-92. PubMed ID: 2519184
[TBL] [Abstract][Full Text] [Related]
4. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
5. T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
[TBL] [Abstract][Full Text] [Related]
6. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
Nitta T
No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
[No Abstract] [Full Text] [Related]
7. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes.
Saris SC; Spiess P; Lieberman DM; Lin S; Walbridge S; Oldfield EH
J Neurosurg; 1992 Mar; 76(3):513-9. PubMed ID: 1738033
[TBL] [Abstract][Full Text] [Related]
8. Non-surgical therapy for malignant brain tumours.
Moseley RP; Coakham HB
Br J Hosp Med; 1990 Jun; 43(6):453-8. PubMed ID: 2364239
[TBL] [Abstract][Full Text] [Related]
9. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
Grimm EA
Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948
[No Abstract] [Full Text] [Related]
11. [Adoptive immunotherapy in patients with malignant glioma].
Yoshida S; Takai N; Saito T; Tanaka R
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1930-2. PubMed ID: 3496052
[TBL] [Abstract][Full Text] [Related]
12. Effect of Corynebacterium parvum on tumor growth in the central nervous system of mice.
Conley FK; Remington JS
J Natl Cancer Inst; 1978 Sep; 61(3):827-32. PubMed ID: 278860
[No Abstract] [Full Text] [Related]
13. Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Albright L; Madigan JC; Gaston MR; Houchens DP
Cancer Res; 1975 Mar; 35(3):658-65. PubMed ID: 234790
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
15. Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas.
Yamasaki T; Handa H; Yamashita J; Watanabe Y; Namba Y; Hanaoka M
Cancer Res; 1984 May; 44(5):1776-83. PubMed ID: 6608988
[TBL] [Abstract][Full Text] [Related]
16. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
17. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
18. T-cell immunotherapy for malignant glioma: toward a combined approach.
Dietrich PY; Dutoit V; Tran Thang NN; Walker PR
Curr Opin Oncol; 2010 Nov; 22(6):604-10. PubMed ID: 20739889
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
Blacklock JB; Grimm EA
Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
[No Abstract] [Full Text] [Related]
20. Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
Ströjby S; Eberstål S; Svensson A; Fritzell S; Bexell D; Siesjö P; Darabi A; Bengzon J
J Neuroimmunol; 2014 Sep; 274(1-2):240-3. PubMed ID: 25086876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
